Originally published as JCO Early Release 10.1200/JCO.2006.05.6861 on August 8 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hess, K. R. Articles by Pusztai, L. Search for Related Content PubMed PubMed Citation Articles by Hess, K. R. Articles by Pusztai, L. Social Bookmarking                            What's this?

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

Kenneth R. Hess, Keith Anderson, W. Fraser Symmans, Vicente Valero, Nuhad Ibrahim, Jaime A. Mejia, Daniel Booser, Richard L. Theriault, Aman U. Buzdar, Peter J. Dempsey, Roman Rouzier, Nour Sneige, Jeffrey S. Ross, Tatiana Vidaurre, Henry L. Gómez, Gabriel N. Hortobagyi, Lajos Pusztai

From the Departments of Biostatistics and Applied Mathematics, Pathology, Breast Medical Oncology and Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Breast Cancer Unit and Unité Propre de l'Enseignement Supérieur; Equipe d'Accueil 3535 of the Institut Gustave Roussy, Villejuif, France; Albany Medical College, Albany NY; Departamento de Medicina Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú

Address reprint requests to Lajos Pusztai, MD, DPhil, Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 1354, PO Box 301439, Houston, TX 77230-1439; e-mail: lpusztai{at}mdanderson.org

Purpose We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases.

Patients and Methods One hundred thirty-three patients with stage I-III breast cancer were included. Pretreatment gene expression profiling was performed with oligonecleotide microarrays on fine-needle aspiration specimens. We developed predictors of pCR from 82 cases and assessed accuracy on 51 independent cases.

Results Overall pCR rate was 26% in both cohorts. In the training set, 56 probes were identified as differentially expressed between pCR versus residual disease, at a false discovery rate of 1%. We examined the performance of 780 distinct classifiers (set of genes + prediction algorithm) in full cross-validation. Many predictors performed equally well. A nominally best 30-probe set Diagonal Linear Discriminant Analysis classifier was selected for independent validation. It showed significantly higher sensitivity (92% v 61%) than a clinical predictor including age, grade, and estrogen receptor status. The negative predictive value (96% v 86%) and area under the curve (0.877 v 0.811) were nominally better but not statistically significant. The combination of genomic and clinical information yielded a predictor not significantly different from the genomic predictor alone. In 31 samples, RNA was hybridized in replicate with resulting predictions that were 97% concordant.

Conclusion A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value. This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients).

published online ahead of print at www.jco.org on August 7, 2006.

Supported by grants from the National Cancer Institute (RO1-CA106290), the Breast Cancer Research Foundation, the Gilder Foundation, the Dee Simmons Fund, and the Nellie B. Connally Breast Cancer Research Fund.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. Roepman, H. M. Horlings, O. Krijgsman, M. Kok, J. M. Bueno-de-Mesquita, R. Bender, S. C. Linn, A. M. Glas, and M. J. van de Vijver Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer Clin. Cancer Res., November 15, 2009; 15(22): 7003 - 7011. [Abstract] [Full Text] [PDF]

				P. D. Williams, S. Cheon, D. M. Havaleshko, H. Jeong, F. Cheng, D. Theodorescu, and J. K. Lee Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic Therapy Cancer Res., November 1, 2009; 69(21): 8302 - 8309. [Abstract] [Full Text] [PDF]

				C. Speers, A. Tsimelzon, K. Sexton, A. M. Herrick, C. Gutierrez, A. Culhane, J. Quackenbush, S. Hilsenbeck, J. Chang, and P. Brown Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer Clin. Cancer Res., October 15, 2009; 15(20): 6327 - 6340. [Abstract] [Full Text] [PDF]

				L. Pusztai, J.-H. Jeong, Y. Gong, J. S. Ross, C. Kim, S. Paik, R. Rouzier, F. Andre, G. N. Hortobagyi, N. Wolmark, et al. Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial J. Clin. Oncol., September 10, 2009; 27(26): 4287 - 4292. [Abstract] [Full Text] [PDF]

				C. Min, Z. Yu, K. H. Kirsch, Y. Zhao, S. R. Vora, P. C. Trackman, D. B. Spicer, L. Rosenberg, J. R. Palmer, and G. E. Sonenshein A Loss-of-Function Polymorphism in the Propeptide Domain of the LOX Gene and Breast Cancer Cancer Res., August 15, 2009; 69(16): 6685 - 6693. [Abstract] [Full Text] [PDF]

				A. Grigoriadis, O. L. Caballero, K. S. Hoek, L. da Silva, Y.-T. Chen, S. J. Shin, A. A. Jungbluth, L. D. Miller, D. Clouston, J. Cebon, et al. CT-X antigen expression in human breast cancer PNAS, August 11, 2009; 106(32): 13493 - 13498. [Abstract] [Full Text] [PDF]

				F. Correa Geyer and J. S. Reis-Filho Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet? International Journal of Surgical Pathology, August 1, 2009; 17(4): 285 - 302. [Abstract] [PDF]

				B. Fayard, F. Bianchi, J. Dey, E. Moreno, S. Djaffer, N. E. Hynes, and D. Monard The Serine Protease Inhibitor Protease Nexin-1 Controls Mammary Cancer Metastasis through LRP-1-Mediated MMP-9 Expression Cancer Res., July 15, 2009; 69(14): 5690 - 5698. [Abstract] [Full Text] [PDF]

				C. Liedtke, C. Hatzis, W. F. Symmans, C. Desmedt, B. Haibe-Kains, V. Valero, H. Kuerer, G. N. Hortobagyi, M. Piccart-Gebhart, C. Sotiriou, et al. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer J. Clin. Oncol., July 1, 2009; 27(19): 3185 - 3191. [Abstract] [Full Text] [PDF]

				T. A. DiMeo, K. Anderson, P. Phadke, C. Feng, C. M. Perou, S. Naber, and C. Kuperwasser A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer Cancer Res., July 1, 2009; 69(13): 5364 - 5373. [Abstract] [Full Text] [PDF]

				V. Guarneri and P. Conte Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy Oncologist, July 1, 2009; 14(7): 645 - 656. [Abstract] [Full Text] [PDF]

				D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist PNAS, June 23, 2009; 106(25): 10284 - 10289. [Abstract] [Full Text] [PDF]

				A. M. Sieuwerts, J. Kraan, J. Bolt-De Vries, P. Van Der Spoel, F. Elstrodt, M. Smid, M. Timmermans, B. Mostert, M. Schutte, J. W. M. Martens, et al. Response: Re: Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells J Natl Cancer Inst, June 16, 2009; 101(12): 896 - 897. [Full Text] [PDF]

				M. Lupien, J. Eeckhoute, C. A. Meyer, S. A. Krum, D. R. Rhodes, X. S. Liu, and M. Brown Coactivator Function Defines the Active Estrogen Receptor Alpha Cistrome Mol. Cell. Biol., June 15, 2009; 29(12): 3413 - 3423. [Abstract] [Full Text] [PDF]

				Y. Zhang, J. W.M. Martens, J. X. Yu, J. Jiang, A. M. Sieuwerts, M. Smid, J. G.M. Klijn, Y. Wang, and J. A. Foekens Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer Cancer Res., May 1, 2009; 69(9): 3795 - 3801. [Abstract] [Full Text] [PDF]

				J. S. Parker, M. Mullins, M. C.U. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes J. Clin. Oncol., March 10, 2009; 27(8): 1160 - 1167. [Abstract] [Full Text] [PDF]

				T. Sorlie Introducing Molecular Subtyping of Breast Cancer Into the Clinic? J. Clin. Oncol., March 10, 2009; 27(8): 1153 - 1154. [Full Text] [PDF]

				C. Sotiriou and L. Pusztai Gene-Expression Signatures in Breast Cancer N. Engl. J. Med., February 19, 2009; 360(8): 790 - 800. [Full Text] [PDF]

				J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G. G. Steger, A. Makhson, S. Tjulandin, H. Ludwig, M. Verrill, et al. Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer J. Clin. Oncol., February 1, 2009; 27(4): 526 - 534. [Abstract] [Full Text] [PDF]

				J. Chiquet, A. Smith, G. Grasseau, C. Matias, and C. Ambroise SIMoNe: Statistical Inference for MOdular NEtworks Bioinformatics, February 1, 2009; 25(3): 417 - 418. [Abstract] [Full Text] [PDF]

				F. Andre, B. Job, P. Dessen, A. Tordai, S. Michiels, C. Liedtke, C. Richon, K. Yan, B. Wang, G. Vassal, et al. Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array Clin. Cancer Res., January 15, 2009; 15(2): 441 - 451. [Abstract] [Full Text] [PDF]

				F. Huang, A. Greer, W. Hurlburt, X. Han, R. Hafezi, G. M. Wittenberg, K. Reeves, J. Chen, D. Robinson, A. Li, et al. The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors Cancer Res., January 1, 2009; 69(1): 161 - 170. [Abstract] [Full Text] [PDF]

				O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo Advances in Breast Cancer: Pathways to Personalized Medicine Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999. [Abstract] [Full Text] [PDF]

				M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]

				J. K. Miller, D. L. Shattuck, E. Q. Ingalla, L. Yen, A. D. Borowsky, L. J.T. Young, R. D. Cardiff, K. L. Carraway III, and C. Sweeney Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer Cancer Res., October 15, 2008; 68(20): 8286 - 8294. [Abstract] [Full Text] [PDF]

				J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist, May 1, 2008; 13(5): 477 - 493. [Abstract] [Full Text] [PDF]

				L. Pusztai Current Status of Prognostic Profiling in Breast Cancer Oncologist, April 1, 2008; 13(4): 350 - 360. [Abstract] [Full Text] [PDF]

				E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer Ann. Onc., February 1, 2008; 19(2): 223 - 232. [Abstract] [Full Text] [PDF]

				A. Dhasarathy, M. Kajita, and P. A. Wade The Transcription Factor Snail Mediates Epithelial to Mesenchymal Transitions by Repression of Estrogen Receptor-{alpha} Mol. Endocrinol., December 1, 2007; 21(12): 2907 - 2918. [Abstract] [Full Text] [PDF]

				M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann. Onc., December 1, 2007; 18(12): 1927 - 1934. [Abstract] [Full Text] [PDF]

				K. S. Garman, J. R. Nevins, and A. Potti Genomic strategies for personalized cancer therapy Hum. Mol. Genet., October 15, 2007; 16(R2): R226 - R232. [Abstract] [Full Text] [PDF]

				L. Pusztai, K. Anderson, and K. R. Hess Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer Clin. Cancer Res., October 15, 2007; 13(20): 6080 - 6086. [Abstract] [Full Text] [PDF]

				A. A.N. Rose, F. Pepin, C. Russo, J. E. Abou Khalil, M. Hallett, and P. M. Siegel Osteoactivin Promotes Breast Cancer Metastasis to Bone Mol. Cancer Res., October 1, 2007; 5(10): 1001 - 1014. [Abstract] [Full Text] [PDF]

				L. Gianni Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs J. Clin. Oncol., August 10, 2007; 25(23): 3389 - 3391. [Full Text] [PDF]

				F. Peintinger, K. Anderson, C. Mazouni, H. M. Kuerer, C. Hatzis, F. Lin, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4078 - 4082. [Abstract] [Full Text] [PDF]

				F. Andre, C. Hatzis, K. Anderson, C. Sotiriou, C. Mazouni, J. Mejia, B. Wang, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2061 - 2067. [Abstract] [Full Text] [PDF]

				F. Huang, K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P. Shaw, and E. Clark Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection Cancer Res., March 1, 2007; 67(5): 2226 - 2238. [Abstract] [Full Text] [PDF]

				L. Pusztai Chips to Bedside: Incorporation of Microarray Data into Clinical Practice Clin. Cancer Res., December 15, 2006; 12(24): 7209 - 7214. [Full Text] [PDF]